Sulfisoxazole Acetyl

Summary

Sulfisoxazole Acetyl (CHEMBL1200910) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 309.34 Da · C13H15N3O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200910
Name	Sulfisoxazole Acetyl
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6662
Molecular formula	C13H15N3O4S
Molecular weight	309.34
InChIKey	JFNWFXVFBDDWCX-UHFFFAOYSA-N

SMILES: CC1=C(ON=C1C)N(C(=O)C)S(=O)(=O)C2=CC=C(C=C2)N

IUPAC name: N-(4-aminophenyl)sulfonyl-N-(3,4-dimethyl-1,2-oxazol-5-yl)acetamide

Also known as: Acetyl sulfafurazole, Acetyl sulfisoxazole, Acetylsulfafurazole, Acetylsulfisoxazole, Gantrisin, Gantrisin pediatric, Lipo gantrisin, NSC-759138, Sulfafurazole acetyl, Sulfisoxazole acetyl, Sulfisoxizole acetyl, SULFISOXAZOLE ACETYL

Patent coverage: 919 distinct patent families (3,482 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Endothelin-1 receptor.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).